NMS Labs
3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, DABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/03/2014 07:36
Last Report Issued 10/23/2013 11:54

88888
Clinical Example Report
Attn: IT Department
3701 Welsh Road
Willow Grove, PA 19090

Patient Name 4033SP
Patient ID 4033SP
Chain 13003673
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 13003673

Received 10/23/2013 11:49

Sample ID 13003673-001
Matrix Serum or Plasma
Patient Name 4033SP
Patient ID 4033SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4033SP Pyrazinamide, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Pyrazinamide	None Detected	mcg/mL	0.30	
The range of clinically acceptable values for optimized therapy for pyrazinamide is 20-60 mcg/mL. A single oral 27 mg/kg oral dose of pyrazinamide produced mean peak plasma concentrations of 39 mcg/mL after one hour. A repeated dose of 23.9 mg/kg produced mean peak plasma concentrations of 32.9 mcg/mL (range, 21.6-44.2 mcg/mL).				